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EVIDENCE BASED NEURO-ONCOLOGY
Choice of therapeutic anti-seizure medication in patients with brain tumour
Altaf Ali Laghari,1 Syed Ijlal Ahmed,2 Namra Qadeer,3 Muhammad Shahzad Shamim4

Abstract
Seizures are common in patients with brain tumours,
even though prophylactic anti-seizure treatment for all
patients with brain tumours is not recommended. Newer
anti-epileptic drugs have shown benefits that outweigh
the side effects of treatment and can also be given in
combination with traditional anti-epileptic drugs. The
authors have reviewed the literature on the various
combinations of anti-epileptics in patients with seizures
and brain tumours.

Keywords: Seizures, anti-epileptic drugs, brain
tumours.

Introduction
Seizures may be the presenting symptom of a brain
tumour, which is reported in a substantial number of
patients, especially those with intra-axial, supratentorial
brain tumours. It is postulated that the tissue in and
around brain tumours may exhibit epileptogenic
properties due to dysregulated neuronal activity,
impaired glial cell function, and modified vascularity.1 The
presence of abnormal, neoplastic tissue leads to structural
and functional alteration of surrounding tissue due to
oedema, vascular insufficiency, inflammation, and release
of metabolically active molecules, all of which may
predispose to seizure activity. Understanding these
changes may lead to a better control of seizures in
patients with brain tumours. In this article we aim to
review
literature
addressing
pharmaceutical
management of seizures in patients with brain tumours.
This review will not address the role of prophylactic antiepileptics in patients with brain tumours.

Review Of Evidence
Valproic acid or valproate, is a conventional anti-epileptic
drug with properties of a histone deacetylase inhibitor
(HDACi). HDACi plays a key role in gene expression and
epigenetic regulation and has also been used as an
anticancer agent. Redjal et al.2, report valproate to be
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associated with improved survival in patients with high
grade glioma and GBM in a dose-dependent manner.
However, in patients with grade II and III gliomas, it is
associated with an 18% increased risk of tumour
progression or death, and every additional 100g of
valproate raises the risk of progression or death by 10%.
These are alarming observations and require further
prospective validation. Van Breemen et al.3, studied the
use of both valproate as first choice, and in combination
with newer anti-epileptic levetiracetam. The combination
of these two medications resulted in 81.5% responders,
with 55.6% of patients showing a tangible decline in
seizure frequency. They recommended that the
combination of an older with newer drug, can be a useful
therapeutic option in brain tumour patients with resistant
seizures.
In another study Novy J et al.4, retrospectively reviewed
the use of pregabalin (non-enzyme-inducing antiepileptic
drug) in GBM patients with seizures. All subjects
experienced at least a 50% seizure reduction. The authors
recommended pregabalin as an effective anti-epileptic in
patients with brain tumours and seizures. Its quick
titration also makes it a good alternative in subjects
experiencing frequent seizures and the drug can also be
used in combination with other anti-epileptics like
levetiracetam, lamotrigine, topiramate, gabapentin and
valproic acid as a first-line treatment.4 However, so far it is
not being used as a first line anti-epileptic drug.
Zonisamide (ZNS), a second-generation anti-epileptic
drug, has demonstrated efficacy as an add-on in
refractory epilepsy with simple and complex partial
seizures, with or without secondary generalization. The
pharmacokinetics of ZNS include rapid absorption, high
bioavailability, and a long elimination half-life. The most
common adverse effects of ZNS (somnolence, weight loss,
and cognitive impairment) were mild to moderate and
there were no interactions with concomitant antiepileptic drugs.ZNS does not alter patients' perception of
their quality of life and there also appears to be a
significant improvement in distress related to cognitive
disturbances and social functions.5
In patients with brain tumours, phenytoin used to be the
drug of choice for prophylactic peri-operative
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administration, as well as for seizure control. However, it
was associated with drug interactions due to its induction
of CYP P450 enzymes. In contrast, levetiracetam is not
metabolized by the CYP complex in the liver and
undergoes renal excretion with minimal drug interaction.
In a phase 2 prospective randomized trial, Iuchi et al.6,
showed levetiracetamto have a significantly lower
incidence of perioperative seizures (1.4%) compared to
phenytoin (15.1%). In addition, levetiracetam appeared a
a safer drug, and treatment was completed in all patients,
compared to phenytoin that had to be withdrawn in 6.8%
of patients. Levetiracetam, in several studies including a
meta-analysis, has shown efficacy comparable to
phenytoin, with reduced cost and adverse effects.7 Also,
due to the advantage of not having to check its serum
levels, easy titration and minimal drug interactions,
levetiracetam is fast becoming the first line anti-epileptic
for brain tumour patients.
Tumour localization in the frontal lobe and levetiracetam
treatment have been associated with high risk of neuropsychiatric adverse effects in patients with brain tumour
related epilepsy. This leads to poor compliance and
higher dropout rates, and therefore, these patients need
to be closely monitored as outpatients.8 The other
adverse effect to look for is somnolence, as reported by
Rosati A et al.9, in a prospective study, where although 73
of 82 (91%) glioma patients were seizure free with
levetiracetam as monotherapy, somnolence was
occasionally reported in the initial period of therapy.

c

a role in effectivity of treatment and survival. Both
valproate and carbamazepine have HDACi activities,
while valproate and levetiracetam reduce the activity of
MGMT, a DNA-repair molecule implicated in resistance to
alkylating agents used for chemotherapy.10 The use of
such drugs for purposes other than seizure control has at
the moment, very little evidence to support its use, but
does present an interesting area of research.11

Conclusion
Seizures in patients with brain tumour can be managed
effectively by the use of one of many anti-epileptic drugs,
either as monotherapy, or as combinations. The choice of
anti-epileptic drugs, depends on several factors and has
to be individualized according to patients’ response.
Newer drugs such as levetiracetam, have better tolerance
and safety profile, and may be employed either as
monotherapy, or as an add-on with conventional antiepileptic drugs.
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